Clinical trial
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With…
NCT00083525 · Heidelberg Pharma AG, Industry · Completed
Key facts
| NCT number | NCT00083525 |
|---|---|
| Title | Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies |
| Lead sponsor | Heidelberg Pharma AG, Industry |
| Collaborators | United States Department of Defense U.S. Fed |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Malignancies |
| Intervention type | Drug |
| Interventions | WX-UK1 in combination with Capecitabine |
| Enrollment | 33 |
| Start date | May 1, 2004 |
| First posted | May 26, 2004 |
| Last update posted | Jan 24, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: